There is limited awareness of cannabinoid hyperemesis syndrome among psychiatrists and physicians, which results in diagnostic failure and inadequate treatment. In this article, Dr Rehman and colleagues discuss the successful management of such a case, including recognition of the condition, diagnostic measures, treatment and long‐term follow‐up.

Spectrum of speech signals have fre q uenc y Codebook training is done using LBG algorithm [2]. Wideband components from 50Hz to 7 kHz (Wideband speech). However, speech from training data is taken and is fed into two branches. From due to historical reasons speech is band-pass filtered between 300 one branch, Narrowband speech is extracted. This is segmented into Hz-3.4 kHz in PSTN networks and this speech is referred to as frames and from each frame, 10 th order LPC co-efficients are narrowband speech. The missing bandwidth in narrow band extracted. LPC co-efficients are converted to LSFs [1]. These LSF speech contributes to speech q uality and intelligibility. This paper values are used for Narrow band code book design and to calculate addresses the problem of artificial bandwidth extension of the GMM parameters. From the other branch, wideband LPC co narrowband speech to wideband speech. The proposed method efficients are obtained which are converted to wideband LSFs. These for bandwidth extension is based on statistical recovery using LSFs are used to build the wideband codebook.Gaussian Mixture Model (GMM) for spectral envelope parameters and spectral shifting method is used for excitation extension.

Phenylketonuria (PKU) is a rare inborn error of metabolism. It is caused by the deficiency of phenylalanine hydroxylase, an enzyme which converts phenylalanine to tyrosine and can cause severe learning disability in children if untreated. Drs Balaji et al. describe a case of an adult female with phenylketonuria and schizophrenia who was non‐compliant with the PKU diet. The case raises questions about the management of this condition in adults.

There is a considerable paucity of empirical data on the use of clozapine in people with intellectual disability, and to the authors’ knowledge these are the first published data on its use in a patient with trisomy 5p and with a diagnosis of schizophrenia. In this case we describe a patient with learning difficulties and a diagnosis of trisomy 5p and schizophrenia that has responded remarkably to clozapine treatment despite numerous additional clinical risk factors.

AimRisperidone has been recommended for the management of disruptive behaviour disorders in children with learning disabilities. This study explored the effects of Risperidone on absolute body weight in children with learning disabilities who received Risperidone for disruptive behaviour disorders.MethodologyData was collected for children (n = 70) with learning disabilities who were prescribed Risperidone for disruptive behaviour disorders in out patient clinic. Weight, height and BMI were recorded at the first appointment and at the follow up for up to one year. Data was analysed to find any changes in weight and BMI during the course of treatment with Risperidone.ResultsMean weight gain for the sample was 6.1 kg (sd = 2.7), 1.7 kg more than expected in one year which was statistically significant (t = 6.2, df = 69, p < 0.001). Mean BMI change was 1.51 kg; significantly larger than the mean expected BMI change of 0.62 of this sample (t = 4.98, df = 1.6, P = 0.001). Change in BMI was more for girls, 2.17 (sd = 1.00) compared with boys 1.36 (sd = 1.18), but this was not significant (t = 1.90, df = 49, p = 0.06). There is no significant relationship between Risperidone dose and weight gain (Pearson's r = 0.21, p = 0.42) and BMI (Pearson's r = 0.03, p = 1.00).ConclusionRisperidone should be used with caution in children where weight gain could have long lasting impact. Prescribing clinicians should obtain baseline measures of weight, height, BMI and monitor them at regular intervals. Emphasis should be placed on life style interventions such as diet, physical activities etc. Further comparable studies with larger sample sizes using more homogenous diagnostic samples are needed.